Learn more

DECIPHERA PHARMACEUTICALS LLC

Overview
  • Total Patents
    279
  • GoodIP Patent Rank
    13,946
  • Filing trend
    ⇧ 66.0%
About

DECIPHERA PHARMACEUTICALS LLC has a total of 279 patent applications. It increased the IP activity by 66.0%. Its first patent ever was published in 2003. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are ALMIRALL AG, ADAMS NICHOLAS D and CYTOPIA PTY LTD.

Patent filings per year

Chart showing DECIPHERA PHARMACEUTICALS LLCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Flynn Daniel L 228
#2 Kaufman Michael D 166
#3 Petillo Peter A 117
#4 Vogeti Lakshminarayana 37
#5 Patt William C 37
#6 Caldwell Timothy Malcolm 33
#7 Smith Bryan D 25
#8 Daniel L Flynn 21
#9 Samarakoon Thiwanka 19
#10 Michael D Kaufman 19

Latest patents

Publication Filing date Title
US2021046059A1 Methods of treating gastrointestinal stromal tumors
WO2021030404A1 Methods and compositions for treating vascular malformations
WO2021030405A1 Ripretinib for treating gastrointestinal stromal tumors
WO2020257180A1 Aminopyrimidine amide autophagy inhibitors and methods of use thereof
US2020354346A1 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US2020354352A1 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
US2020253973A1 Methods of treating disorders using csf1r inhibitors
JP2019131610A Methods for inhibiting tie2 kinase useful in treatment of cancer
BR112020015572A2 combination therapy for the treatment of mastocytosis
AU2019215081A1 Combination therapy for the treatment of gastrointestinal stromal tumors
US2017079966A1 Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
WO2016061231A1 Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
EP3206752A1 Inhibition of trk kinase mediated tumor growth and disease progression
US2015246033A1 Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US2014275016A1 N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
US2014343103A1 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
CN105120864A 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
CN105228620A Represent N-acyl group-N '-(pyridine-2-base) urea and the analog of anticancer and antiproliferative activity
WO2014145015A2 Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145023A1 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities